CORRECTED: Webcast Alert: Immunicon Corporation Announces Its Second Quarter 2006 Financial Earnings Conference Call and Webcast.

HUNTINGDON VALLEY, Pa. -- Byron D. Hewett, President and CEO, and other members of senior management will provide an Immunicon (NASDAQ-NM:IMMC) update and discuss results via Webcast and conference call on Wednesday, August 2, 2006, at 9:00 a.m. ET.

What:    Immunicon Corporation's Second Quarter 2006 Financial
                 Earnings Call and Webcast

        When:    Wednesday, August 2, 2006, at 9:00 a.m. ET

        How:     To participate in the live call by telephone, the
                 dial-in number for domestic U.S. listeners is
                 888-362-4820 using passcode: 14250885. International
                 callers may dial 617-597-5345 using passcode:
                 14250885. In addition, a live audio Webcast of the
                 call will be available online at Immunicon's
                 corporate Web site at http://www.immunicon.com.
                 Webcast participants are encouraged to log on to the
                 site at least 15 minutes prior to the scheduled start
                 time to register, download, and install any necessary
                 audio software.

        Contact: Denise Portner, Tierney Communications, 215-790-4395

Following the call, a Webcast audio replay will be available on the Company's Web site for 30 days through Friday, September 1, 2006. In addition, a dial-in replay will be maintained for 5 days through Monday, August 7, and can be accessed by dialing 888-286-8010 (U.S. listeners) or 617-801-6888 (International dialers) using reservation code: 67114176.

The conference call audio is also being distributed over the Thomson/CCBN Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through the Thomson/CCBN individual investor center at www.earnings.com or by visiting any of the investor sites in the Thomson/CCBN Individual Investor Network. Institutional investors can access the call via Thomson/CCBN password-protected event management site, StreetEvents (www.streetevents.com).

About Immunicon Corporation

Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com.

Forward-Looking Statements

The information contained in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to Immunicon's anticipated net cash burn for 2006, Immunicon's funding strategy for commercialization activities and key product and clinical development programs and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date of this press release, reflect management's current expectations and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by Immunicon's forward-looking statements. These factors include, but are not limited to, risks and uncertainties associated with: Immunicon's dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of Immunicon's product candidates; Immunicon's ability to use licensed products and to obtain new licenses from third parties; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon's customers for Immunicon's products; compliance with applicable manufacturing standards; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; retaining key management or scientific personnel; delays in the development of new products or to planned improvements to Immunicon's products; effectiveness of Immunicon's products compared to competitors' products; protection of Immunicon's intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission.

"Immunicon" and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. "CellSpotter," "CellTracks" and "AutoPrep" are registered trademarks of Immunivest Corporation, a wholly-owned subsidiary of Immunicon Corporation. CellTracks Analyzer II is a trademark of Immunivest Corporation. "CellSearch" is a trademark of Johnson & Johnson. All other trademarks or servicemarks appearing in this report are the property of their respective holders. ALL RIGHTS RESERVED.